Locations:
SearchSGLT2 inhibitors already show heart benefits in diabetes patients
For patients with heart failure with preserved ejection fraction (HFpEF), current treatments address only accompanying conditions and symptoms. Therapy commonly involves treating high blood pressure and coronary artery disease, and encouraging weight loss and smoking cessation.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
However, in 2020 we may see FDA approval of a class of medications, SGLT2 inhibitors, for the treatment of HFpEF. These medications already have shown reduced risk of cardiovascular death and heart failure hospitalization in patients with type 2 diabetes. Research is ongoing — yet promising — in HFpEF patients without diabetes.
In this video, learn more about why SGLT2 inhibitors are one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items
Dedicated committee and surgical fellowship strive for sustainability, energy efficiency, waste reduction
Next-generation mRNA vaccines are among the advancements likely to change healthcare this year
$50 million pledge will help remove sources of lead exposure from Cleveland homes
How to empower caregivers and engage patients in patient safety
Summit to cap off with Annual Top 10 Medical Innovations
The spine surgeon will oversee more than 125 staff physicians in his new role
Merlino rejoins Cleveland Clinic to help execute bold strategic vision